Filing Flows › Comparisons › INO vs ASBP
Inovio Pharmaceuticals vs Aspire-Lakewood Holdings: INO and ASBP compared
Inovio Pharmaceuticals is the larger company: $65K of revenue in its latest quarter (Q1 2025) against $63K for Aspire-Lakewood Holdings (Q2 2026).
Where the money goes: INO and ASBP
Inovio Pharmaceuticals (INO) · Q1 2025
Inovio Pharmaceuticals, Q1 2025: revenue $65K, net loss $19.7M, operating cash flow −$26.9M. The chart follows the revenue to costs, profit and cash.
Aspire-Lakewood Holdings (ASBP) · Q2 2026
Aspire-Lakewood Holdings, Q2 2026: revenue $63K, net loss $1.3M, operating cash flow −$2.1M. The chart follows the revenue to costs, profit and cash.
| Inovio Pharmaceuticals (INO) | Aspire-Lakewood Holdings (ASBP) | |
|---|---|---|
| Latest quarter | Q1 2025 | Q2 2026 |
| Revenue | $65K | $63K |
| Operating margin | n/m | n/m |
| Net earnings | −$19.7M | −$1.3M |
| Operating cash flow | −$26.9M | −$2.1M |
Questions
Which is bigger, Inovio Pharmaceuticals or Aspire-Lakewood Holdings?
Inovio Pharmaceuticals is the larger company: $65K of revenue in its latest quarter (Q1 2025) against $63K for Aspire-Lakewood Holdings (Q2 2026).
More: Inovio Pharmaceuticals earnings · how Inovio Pharmaceuticals makes money · Aspire-Lakewood Holdings earnings · how Aspire-Lakewood Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 13, 2025; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.